

Applicants: Abraham Loyter, et al.  
U.S. Serial No.: 10/511,990  
Filed: as §371 national stage of  
PCT/IL2003/000328, filed April 21, 2003  
Page 2

**Sequence Listing:**

Please replace the Sequence Listing as filed in connection with the subject application with the substitute paper copy of the Sequence Listing attached hereto as **Exhibit C**.

# EXHIBIT C

# SEQUENCE LISTING

<110> Abraham Loyter  
 Adolf Graessman  
 Ahuva Nissim  
 Alexander Krichevsky  
 Nechama Zakai

<120> ANTI-NLS SCFV AND PEPTIDES AND USES THEREOF IN NUCLEAR IMPORT INHIBITION

<130> 73236/JFW/JW

<140> US 10/511,990  
 <141> 2004-10-21

<150> PCT/IL2003/000328  
 <151> 2003-04-21

<150> IL 149279  
 <151> 2002-04-22

<160> 16

<170> PatentIn version 3.3

<210> 1  
 <211> 12  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Random insert of CDR3 region from peptide library - Ab1 DNA

<400> 1  
 attagtagtg at

<210> 2  
 <211> 4  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> CDR3 random insert of Ab1

<400> 2  
 Ile Ser Ser Asp  
 1

<210> 3  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

<220>

12

<223> CDR3 random insert of Ab2 DNA

<400> 3  
gcttttatga agagtggtaa gcgttttatt cat

33

<210> 4  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR3 random insert sequence of Ab2

<400> 4  
Ala Phe Met Lys Ser Gly Lys Arg Phe Ile His  
1 5 10

<210> 5  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> CDR3 random insert sequence of Ab3 DNA

<400> 5  
cattttcatt ataagggtaa gcttcagacg ttt

33

<210> 6  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> CDR3 random insert of Ab3

<400> 6  
His Phe His Tyr Lys Gly Lys Leu Gln Thr Phe  
1 5 10

<210> 7  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> SV40-NLS with extra C

<400> 7  
Pro Lys Lys Lys Arg Lys Val Cys

1 5

<210> 8  
<211> 9  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> SV40-NLS-reverse with extra C

<400> 8

Cys Val Lys Arg Lys Lys Lys Pro Gly  
1 5

<210> 9  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> VprN with extra C

<400> 9

Cys Asn Glu Trp Thr Leu Glu Leu Leu Glu Glu Leu Lys Asn Glu Ala  
1 5 10 15

Val Arg His Phe  
1 20

<210> 10  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> VprC with extra C

<400> 10

Cys Arg His Ser Arg Ile Gly Val Thr Arg Gln Arg Arg Ala Arg Asn  
1 5 10 15

Gly Ala Ser Arg Ser  
20

<210> 11  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>

<223> VprN mutant with extra C

<400> 11

Cys Asn Glu Ala Thr Leu Glu Leu Leu Pro Glu Leu Lys Asn Pro Ala  
1 5 10 15

Val Arg His Phe  
20

<210> 12

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> ARM with extra C

<400> 12

Cys Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn  
1 5 10 15

<210> 13

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Tat short NLS

<400> 13

Cys Gly Arg Lys Lys Arg  
1 5

<210> 14

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> primer LMB3

<400> 14

caggaaacag ctatgac

17

<210> 15

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer fdSEQ

<400> 15

gaattttctg tatgagg

17

<210> 16

<211> 20

<212> PRT

<213> bacteriophage fd

<400> 16

Ala Glu Gly Asp Asp Pro Ala Lys Ala Ala Phe Asp Ser Leu Gln Ala  
1 5 10 15

Ser Ala Thr Glu  
20